Indian pharmaceutical companies are seeking to capture a bigger portion of the $145 billion oncology market in the United States, which is expanding at a compound annual growth rate (CAGR) of 11 percent.
Recently, multiple Indian pharmaceutical companies have obtained approvals from the US Food and Drug Administration (FDA) for oncology generics, indicating a consistent increase in the introduction of complex generics and biosimilar medications into the US market.
The oncology market in the United States was valued at $145.52 billion in 2024 and is expected to reach approximately $416.93 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.1 percent during the forecast period starting in 2025.
